Anthony B. Semedo Sells 2,600 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) Director Anthony B. Semedo sold 2,600 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total transaction of $74,022.00. Following the sale, the director now owns 33,059 shares of the company's stock, valued at $941,189.73. This represents a 7.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Artivion Stock Up 0.1%

AORT stock traded up $0.03 during midday trading on Thursday, hitting $29.79. The company's stock had a trading volume of 290,416 shares, compared to its average volume of 328,143. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $32.33. The firm has a market capitalization of $1.27 billion, a P/E ratio of -1,489.50 and a beta of 1.54. The firm has a 50-day simple moving average of $25.52 and a 200-day simple moving average of $27.37.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Stifel Nicolaus lowered their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Finally, Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Artivion currently has an average rating of "Buy" and an average price target of $31.40.

Institutional Investors Weigh In On Artivion

Institutional investors have recently modified their holdings of the company. Next Century Growth Investors LLC raised its stake in Artivion by 107.6% during the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock worth $25,140,000 after acquiring an additional 530,122 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in Artivion during the 1st quarter worth $7,650,000. Wasatch Advisors LP raised its stake in Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after acquiring an additional 226,160 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Artivion in the fourth quarter valued at $5,573,000. Finally, First Trust Advisors LP acquired a new position in Artivion in the fourth quarter valued at $4,771,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.